Myozyme
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pompe Disease Late-Onset
Conditions
Pompe Disease Late-Onset, Glycogen Storage Disease Type II GSD II
Trial Timeline
Apr 1, 2003 → Aug 1, 2006
NCT ID
NCT00765414About Myozyme
Myozyme is a phase 2 stage product being developed by Sanofi for Pompe Disease Late-Onset. The current trial status is completed. This product is registered under clinical trial identifier NCT00765414. Target conditions include Pompe Disease Late-Onset, Glycogen Storage Disease Type II GSD II.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00268944 | Phase 3 | Completed |
| NCT00125879 | Phase 2/3 | Completed |
| NCT00250939 | Phase 2 | Completed |
| NCT00074932 | Pre-clinical | Completed |
| NCT00059280 | Phase 2/3 | Completed |
| NCT00765414 | Phase 2 | Completed |
| NCT00763932 | Phase 2 | Completed |
| NCT00053573 | Phase 1/2 | Completed |
Competing Products
20 competing products in Pompe Disease Late-Onset
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| S-606001 + Placebo | Shionogi | Phase 2 | 52 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| GZ402666 | Sanofi | Phase 1 | 32 |
| alglucosidase alfa + Placebo | Sanofi | Phase 3 | 76 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| glucosidase alfa | Sanofi | Pre-clinical | 22 |
| Alglucosidase alfa | Sanofi | Approved | 84 |
| Avalglucosidase Alfa | Sanofi | Phase 2 | 51 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| Myozyme | Sanofi | Phase 3 | 76 |
| alglucosidase alfa | Sanofi | Approved | 84 |
| alglucosidase alfa | Sanofi | Pre-clinical | 22 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 3 | 76 |
| Myozyme® (alglucosidase alfa) + Myozyme® (alglucosidase alfa) | Sanofi | Approved | 84 |
| ALGLUCOSIDASE ALFA | Sanofi | Approved | 84 |
| alglucosidase alfa + alglucosidase alfa | Sanofi | Approved | 84 |
| Avalglucosidase alfa (GZ402666) + Alglucosidase alfa (GZ419829) | Sanofi | Phase 2 | 51 |
| Myozyme | Sanofi | Phase 2 | 51 |
| recombinant human acid alpha-glucosidase (rhGAA) | Sanofi | Phase 2 | 51 |
| Alglucosidase Alfa + Methotrexate + Rituximab | Sanofi | Approved | 84 |